A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations

 
• By Sarah Karlin-Smith

Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.

shredded paper
Medicare wants drug companies to keep confidential and later destroy materials related to a drug subject to government negotiations. • Source: Shutterstock

More from Pricing Debate

More from Market Access